Quadrant Capital Group’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,520
| Closed | -$17.9K | – | 2166 |
|
|
2025
Q1 | $17.9K | Buy |
2,520
+2,058
| +445% | +$14.6K | ﹤0.01% | 2065 |
|
|
2024
Q4 | $5.39K | Buy |
462
+419
| +974% | +$4.89K | ﹤0.01% | 2282 |
|
|
2024
Q3 | $884 | Sell |
43
-570
| -93% | -$11.7K | ﹤0.01% | 2609 |
|
|
2024
Q2 | $13.7K | Buy |
613
+231
| +60% | +$5.17K | ﹤0.01% | 2007 |
|
|
2024
Q1 | $10.5K | Sell |
382
-94
| -20% | -$2.59K | ﹤0.01% | 2085 |
|
|
2023
Q4 | $14.5K | Buy |
476
+436
| +1,090% | +$13.3K | ﹤0.01% | 1933 |
|
|
2023
Q3 | $1.27K | Buy |
40
+9
| +29% | +$285 | ﹤0.01% | 2458 |
|
|
2023
Q2 | $1.27K | Sell |
31
-166
| -84% | -$6.77K | ﹤0.01% | 2479 |
|
|
2023
Q1 | $7.34K | Buy |
197
+179
| +994% | +$6.67K | ﹤0.01% | 2142 |
|
|
2022
Q4 | $628 | Sell |
18
-148
| -89% | -$5.16K | ﹤0.01% | 2596 |
|
|
2022
Q3 | $9K | Hold |
166
| – | – | ﹤0.01% | 1931 |
|
|
2022
Q2 | $9K | Buy |
166
+130
| +361% | +$7.05K | ﹤0.01% | 1728 |
|
|
2022
Q1 | $3K | Sell |
36
-25
| -41% | -$2.08K | ﹤0.01% | 2072 |
|
|
2021
Q4 | $7K | Sell |
61
-79
| -56% | -$9.07K | ﹤0.01% | 1772 |
|
|
2021
Q3 | $19K | Buy |
140
+80
| +133% | +$10.9K | ﹤0.01% | 1265 |
|
|
2021
Q2 | $10K | Buy |
60
+28
| +88% | +$4.67K | ﹤0.01% | 1575 |
|
|
2021
Q1 | $3K | Buy |
+32
| New | +$3K | ﹤0.01% | 1967 |
|
|
2020
Q2 | – | Sell |
-15
| Closed | – | – | 2344 |
|
|
2020
Q1 | $0 | Buy |
+15
| New | – | ﹤0.01% | 2216 |
|